These Pharmaceutical Companies Are Making a Killing Off the Opioid Crisis | The Nation
Amphastar Pharmaceuticals, for instance, raised the average wholesale price of its naloxone, which can be injected or outfitted off-label with an atomizer for intranasal use, from $20.34 to $39.60, according to a December 2016 paper in The New England Journal of Medicine. The price of the popular Narcan nasal spray, manufactured by Adapt Pharma and approved in 2015, has not been raised, but it came on the market in 2015 at a high average wholesale price of $150. The largest price hike was for Evzio, an auto-injector device designed for easy use by laypersons. In 2014, a two-dose package of Evzio, manufactured by kaléo, cost $690. As of 2016, it cost $4,500. That’s more than a 500 percent increase.